Interview: Jaw-Jou Kang, former Director General, Taiwan Food & Drug…
Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future…
Address: No.161-2, Kunyang St., Nangang Dist., Taipei City 115, Taiwan
Tel: (02) 2787-8000
Web: http://www.fda.gov.tw/TC/index.aspx
As food, drugs, and cosmetics are intensively involved in people’s daily life and health as well as medical welfare, the Department of Health has strived to facilitate organizational reformation with its focus placed upon consumer health in terms of food and drug safety. Consolidation of the Bureau of Food Safety, the Bureau of Pharmaceutical Affairs, the Bureau of Food and Drug Analysis and the Bureau of Controlled Drugs into the Taiwan Food and Drug Administration (TFDA) was completed on January 1st, 2010, following the promulgation of the TFDA Organization Act on June 3rd, 2009.
Such organizational reformation tends to streamline the process from policy planning to execution, and to increase administration efficiency. Information relating to food and drug safety is released to the public more swiftly, allowing consumers safe and quality food and drugs. TFDA will endeavor to meet the vision to safeguard national health and lead the nation to a new era of food and drug management.
Vision
The vision of TFDA is to safeguard national health and lead the nation to a new era of food and drug management.
Mission
TFDA has the missions to safeguard food and drug safety, to begin a new technology era, and to create a safe consumer environment.
Jaw-Jou Kang, former Director General of Taiwan Food & Drug Administration (TFDA) discusses the key successes the company has had since 2010, where it is looking to in the future…
In January 2010, the Taiwan FDA was newly created from four existing agencies. What was the vision behind the creation of this new organisation? What did the government want to…
In an exclusive interview, Amy Huang, general manager of OBI Pharma, shares her plans to bolster the international development of the company and further strengthen its expertise throughout the drug…
Wu Tsung-Tsong, Minister Without Portfolio of the Republic of China (Taiwan) supervises and coordinates Taiwan’s Biomedical Industry Innovation Program. In this exclusive interview, he documents his main priorities and the…
Leveraging Taiwan’s remarkable talent pool in chemistry, some of the country’s fastest-growing companies have been concentrating their efforts on technology platforms that allow them to develop a plethora of potentially…
Johnsee Lee, a leading figure in the Taiwanese biotech and pharmaceutical sectors and Chairman of Taiwan Bio Industry Organization, the largest and one of the most influential biotechnology associations in…
Founded in 2012, Senhwa Biosciences is mainly engaged in the development and clinical study of small molecule drugs to treat various types of cancer, and its drug development pipelines include…
Wayne Wang, director general of Hsinchu Science Park (HSP), the country’s largest and oldest innovation cluster and the first in Taiwan to establish a science park exclusively dedicated to the…
Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s…
Derek Wang, Chairman of the board of the China Chemical & Pharmaceutical Group (CCPG), one of the leading pharmaceutical groups in Taiwan, provides insights into his strategies to consolidate CCPG’s…
Wang Yu Pei, general manager of Nang Kuang Pharmaceutical, Taiwan’s indisputable market leader for injectable products, provides insights into the global ambitions of the company as Nang Kuang is about…
With more than 100 peer-reviewed articles published and more than ten thousand citations, Guochuan Emil Tsai, founder and CEO of SyneuRx and Professor at the department of Psychiatry and Behavioral…
Ko-Chung Lin, founder and CEO of PharmaEssentia, documents the main specificities of the company’s groundbreaking ropeginterferon alfa-2b, a once-every-two-week interferon displaying a unique toxicity profile. In this regard, Mr. Lin…
Lee-Cheng (L-C) Liu, President and CEO of EirGenix, one of Taiwan’s fastest growing companies in the biotech field, documents the progress made in the set-up of EirGenix’s new commercial biomanufacturing…
See our Cookie Privacy Policy Here
